이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Arbutus Biopharma 대차 대조표 상태
재무 상태 기준 확인 5/6
Arbutus Biopharma 의 총 주주 지분은 $114.6M 이고 총 부채는 $6.4M, 이는 부채 대 자기자본 비율을 5.6% 로 가져옵니다. 총자산과 총부채는 각각 $150.3M 및 $35.7M 입니다.
주요 정보
5.6%
부채 비율
US$6.40m
부채
| 이자 보상 비율 | n/a |
| 현금 | US$129.24m |
| 주식 | US$114.64m |
| 총 부채 | US$35.65m |
| 총 자산 | US$150.29m |
최근 재무 상태 업데이트
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10
We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Recent updates
Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition
Mar 12재무 상태 분석
단기부채: ABUS 의 단기 자산 ( $135.9M )이 단기 부채( $20.3M ).
장기 부채: ABUS 의 단기 자산( $135.9M )이 장기 부채( $15.4M ).
부채 대 자본 내역 및 분석
부채 수준: ABUS 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: ABUS 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 5.6% 로 증가했습니다.
대차 대조표
현금 런웨이 분석
과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.
안정적인 현금 활주로: ABUS 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.
예측 현금 활주로: ABUS 1.7 1.3 1.7 % 매년.